Carolyn L Westhoff1, Hua Guo2, Zhong Wang2, Hanina Hibshoosh2, Margaret Polaneczky3, Malcolm C Pike4, Richard Ha5. 1. Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, PH 16-69, 630 West 168th Street, New York, NY, 10032, USA. clw3@columbia.edu. 2. Department of Pathology, Columbia University Irving Medical Center, New York, NY, USA. 3. Department of Obstetrics and Gynecology, Weill-Cornell Medical Center, New York, NY, USA. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Department of Radiology, Columbia University Irving Medical Center, New York, NY, USA.
Abstract
PURPOSE: The proliferation of breast epithelial cells increases during the luteal phase of the menstrual cycle, when they are exposed to progesterone, suggesting that ulipristal acetate, a selective progestin-receptor modulator (SPRM), may reduce breast cell proliferation with potential use in breast cancer chemoprevention. METHODS: Women aged 18-39 were randomized 1:1 to ulipristal 10-mg daily or to a combination oral contraceptive (COC) for 84 days. Participants underwent a breast biopsy and breast MRI at baseline and at end of study treatment. Proliferation of breast TDLU cells was evaluated by Ki67 immunohistochemical stain. We evaluated the breast MRIs for background parenchymal enhancement (BPE). All slides and images were masked for outcome evaluation. RESULTS: Twenty-eight treatment-compliant participants completed the study; 25 of whom had evaluable Ki67 results at baseline and on-treatment. From baseline to end of treatment, Ki67 % positivity (Ki67%+) decreased a median of 84% in the ulipristal group (N = 13; 2-sided p (2p) = 0.040) versus a median increase of 8% in the COC group (N = 12; 2p = 0.85). Median BPE scores decreased from 3 to 1 in the ulipristal group (p = 0.008) and did not decrease in the COC group. CONCLUSION: Ulipristal was associated with a major decrease in Ki67%+ and BPE. Ulipristal would warrant further investigation for breast cancer chemoprevention were it not for concerns about its liver toxicity. Novel SPRMs without liver toxicity could provide a new approach to breast cancer chemoprevention. TRIAL REGISTRATION: NCT02922127, 4 October 2016.
PURPOSE: The proliferation of breast epithelial cells increases during the luteal phase of the menstrual cycle, when they are exposed to progesterone, suggesting that ulipristal acetate, a selective progestin-receptor modulator (SPRM), may reduce breast cell proliferation with potential use in breast cancer chemoprevention. METHODS: Women aged 18-39 were randomized 1:1 to ulipristal 10-mg daily or to a combination oral contraceptive (COC) for 84 days. Participants underwent a breast biopsy and breast MRI at baseline and at end of study treatment. Proliferation of breast TDLU cells was evaluated by Ki67 immunohistochemical stain. We evaluated the breast MRIs for background parenchymal enhancement (BPE). All slides and images were masked for outcome evaluation. RESULTS: Twenty-eight treatment-compliant participants completed the study; 25 of whom had evaluable Ki67 results at baseline and on-treatment. From baseline to end of treatment, Ki67 % positivity (Ki67%+) decreased a median of 84% in the ulipristal group (N = 13; 2-sided p (2p) = 0.040) versus a median increase of 8% in the COC group (N = 12; 2p = 0.85). Median BPE scores decreased from 3 to 1 in the ulipristal group (p = 0.008) and did not decrease in the COC group. CONCLUSION: Ulipristal was associated with a major decrease in Ki67%+ and BPE. Ulipristal would warrant further investigation for breast cancer chemoprevention were it not for concerns about its liver toxicity. Novel SPRMs without liver toxicity could provide a new approach to breast cancer chemoprevention. TRIAL REGISTRATION: NCT02922127, 4 October 2016.
Authors: F Lakha; P C Ho; Z M Van der Spuy; K Dada; R Elton; A F Glasier; H O D Critchley; A R W Williams; D T Baird Journal: Hum Reprod Date: 2007-07-03 Impact factor: 6.918
Authors: H J Kloosterboer; G H Deckers; W G Schoonen; R G Hanssen; U M Rose; P M Verbost; J G Hsiu; R F Williams; G D Hodgen Journal: Steroids Date: 2000 Oct-Nov Impact factor: 2.668
Authors: Barbara J Attardi; Janet Burgenson; Sheri A Hild; Jerry R Reel; Richard P Blye Journal: Mol Cell Endocrinol Date: 2002-02-25 Impact factor: 4.102
Authors: Douglas K Owens; Karina W Davidson; Alex H Krist; Michael J Barry; Michael Cabana; Aaron B Caughey; Chyke A Doubeni; John W Epling; Martha Kubik; C Seth Landefeld; Carol M Mangione; Lori Pbert; Michael Silverstein; Chien-Wen Tseng; John B Wong Journal: JAMA Date: 2019-09-03 Impact factor: 56.272
Authors: David T Baird; Audrey Brown; Linan Cheng; Hilary O D Critchley; Suiqin Lin; Nitish Narvekar; Alistair R W Williams Journal: Steroids Date: 2003-11 Impact factor: 2.668
Authors: Thomas E Bartlett; Iona Evans; Allison Jones; James E Barrett; Shaun Haran; Daniel Reisel; Kiriaki Papaikonomou; Louise Jones; Chiara Herzog; Nora Pashayan; Bruno M Simões; Robert B Clarke; D Gareth Evans; Talayeh S Ghezelayagh; Sakthivignesh Ponandai-Srinivasan; Nageswara R Boggavarapu; Parameswaran G Lalitkumar; Sacha J Howell; Rosa Ana Risques; Angelique Flöter Rådestad; Louis Dubeau; Kristina Gemzell-Danielsson; Martin Widschwendter Journal: Genome Med Date: 2022-06-15 Impact factor: 15.266